These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 15252828)

  • 1. Paroxetine treatment of delusional disorder, somatic type.
    Hayashi H; Oshino S; Ishikawa J; Kawakatsu S; Otani K
    Hum Psychopharmacol; 2004 Jul; 19(5):351-2; 1p following 352. PubMed ID: 15252828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment by paroxetine of delusional disorder, somatic type, accompanied by severe secondary depression.
    Hayashi H; Akahane T; Suzuki H; Sasaki T; Kawakatsu S; Otani K
    Clin Neuropharmacol; 2010; 33(1):48-9. PubMed ID: 19935408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of delusional disorder, somatic type with remarkable improvement of clinical symptoms and single photon emission computed tomograpy findings following modified electroconvulsive therapy.
    Ota M; Mizukami K; Katano T; Sato S; Takeda T; Asada T
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Aug; 27(5):881-4. PubMed ID: 12921924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary obsessive-compulsive disorder related to diaschisis after pontine infarction, successfully treated with paroxetine.
    Matsui T; Saxena S; Kawabe J; Matsunaga H; Kohagura K; Higashiyama S; Kiriike N
    Psychiatry Clin Neurosci; 2007 Apr; 61(2):186-9. PubMed ID: 17362437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible association between delusional disorder, somatic type and reduced regional cerebral blood flow.
    Wada T; Kawakatsu S; Komatani A; Okuyama N; Otani K
    Prog Neuropsychopharmacol Biol Psychiatry; 1999 Feb; 23(2):353-7. PubMed ID: 10368875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Use of fluoxetine in somatic delusional disorder].
    Quarantini Lde C; Rosário-Campos MC; Batista-Neves SC; Miranda-Scippa A; Sampaio AS
    Braz J Psychiatry; 2004 Jun; 26(2):138. PubMed ID: 15517068
    [No Abstract]   [Full Text] [Related]  

  • 7. Improvement of asymmetrical temporal blood flow in refractory oral somatic delusion after successful electroconvulsive therapy.
    Uezato A; Yamamoto N; Kurumaji A; Toriihara A; Umezaki Y; Toyofuku A; Nishikawa T
    J ECT; 2012 Mar; 28(1):50-1. PubMed ID: 21983760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose paroxetine treatment for an adolescent with obsessive-compulsive disorder comorbid with Asperger's disorder.
    Sasayama D; Sugiyama N; Imai J; Hayashida A; Harada Y; Amano N
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):251. PubMed ID: 19335398
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and tolerability of controlled-release paroxetine.
    Golden RN
    Psychopharmacol Bull; 2003; 37 Suppl 1():176-86. PubMed ID: 14566210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Characteristics of clinical effects of paxil in the treatment of endogenous depression].
    Panteleeva GP; Korenev AN; Khananashvili MM; Oleĭchik IV; Kaleda VG
    Zh Nevrol Psikhiatr Im S S Korsakova; 1998; 98(6):26-31. PubMed ID: 9677694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extremely grotesque somatic delusions in a patient of delusional disorder and its response to risperidone treatment.
    Akahane T; Hayashi H; Suzuki H; Kawakatsu S; Otani K
    Gen Hosp Psychiatry; 2009; 31(2):185-6. PubMed ID: 19269542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clomipramine treatment of delusional disorder, somatic type.
    Wada T; Kawakatsu S; Nadaoka T; Okuyama N; Otani K
    Int Clin Psychopharmacol; 1999 May; 14(3):181-3. PubMed ID: 10435772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo neuroimaging correlates of the efficacy of paroxetine in the treatment of mood and anxiety disorders.
    Kilts C
    Psychopharmacol Bull; 2003; 37 Suppl 1():19-28. PubMed ID: 14566198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paroxetine in child and adolescent outpatients with panic disorder.
    Masi G; Toni C; Mucci M; Millepiedi S; Mata B; Perugi G
    J Child Adolesc Psychopharmacol; 2001; 11(2):151-7. PubMed ID: 11436954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paroxetine treatment of generalized anxiety disorder.
    Sheehan DV; Mao CG
    Psychopharmacol Bull; 2003; 37 Suppl 1():64-75. PubMed ID: 14566202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower gastrointestinal bleeding and paroxetine use: two case reports.
    Blasco-Fontecilla H; de Leon J
    Psychosomatics; 2012; 53(2):184-7. PubMed ID: 22424167
    [No Abstract]   [Full Text] [Related]  

  • 17. Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy.
    Ruhé HG; Booij J; v Weert HC; Reitsma JB; Franssen EJ; Michel MC; Schene AH
    Neuropsychopharmacology; 2009 Mar; 34(4):999-1010. PubMed ID: 18830236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of milnacipran treatment for a patient with delusional disorder, somatic type taking multiple medications for concomitant physical diseases.
    Otani K; Miura Y; Suzuki A; Kinoshita O
    Clin Neuropharmacol; 2010 Jul; 33(4):212-3. PubMed ID: 20386103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of panic disorder: focus on paroxetine.
    Pollack MH; Doyle AC
    Psychopharmacol Bull; 2003; 37 Suppl 1():53-63. PubMed ID: 14566201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A naturalistic study of paroxetine in premenstrual syndrome: efficacy and side-effects during ten cycles of treatment.
    Sundblad C; Wikander I; Andersch B; Eriksson E
    Eur Neuropsychopharmacol; 1997 Aug; 7(3):201-6. PubMed ID: 9213079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.